Clinical trials: Idiopathic Inflammatory Myositis
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: The study duration will be a minimum of 180…
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
- Trial name
- TITAN (NCT06916806)
- Testing
- AZD5492
- Where
- 38 sites in United States, Canada and 8 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE)
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory autoimmune disease, however not all disease responds or remains in response to CD19 targeted CAR-T cells.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc)
- Trial name
- NCT07729995
- Testing
- LMY-922
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Luminary Therapeutics
Dermatomyositis
Interleukin-2 on Active Dermatomyositis
The purpose of this paper is to explore the effect of low-dose IL-2 on refractory dermatomyositis and immunological indexes.
- Trial name
- NCT05495321
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Peking University People's Hospital
Polymyositis, Dermatomyositis
Abatacept Treatment in Polymyositis and Dermatomyositis
The aim of this study is to investigate the efficacy and safety of abatacept in patients with Dermatomyositis (DM) and polymyositis (PM) refractory to conventional treatment using a randomised trial design with delayed start in…
- Trial name
- ARTEMIS (NCT01315938)
- Testing
- Abatacept Active Treatment, Abatacept Delayed-Onset Treatment
- Where
- 2 sites in Czechia, Sweden
- Volunteers
- 20 people
- Sponsor
- Karolinska Institutet
Rheumatic Disease
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating…
- Trial name
- NCT07138898
- Testing
- Methotrexate, Sulfasalazine, Hydroxychloroquine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- NYU Langone Health
Inclusion Body Myositis
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Inclusion body myositis (IBM) is the most common late onset acquired muscle disease. Patients develop progressive weakness that may result in the need for assistive devices including a wheelchair.
- Trial name
- NCT00802815
- Testing
- Etanercept
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Dermatomyositis, Polymyositis
Study and Treatment of Inflammatory Muscle Diseases
This study of inflammatory muscle diseases-polymyositis and dermatomyositis and related disorders-will examine what causes these diseases and describe the clinical features (signs and symptoms) associated with them.
- Trial name
- NCT00001265
- Where
- United States
- Volunteers
- 1,325 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Inclusion Body Myositis (IBM), Feasibility Study
Exercise as Treatment for Patients With Inclusion Body Myositis
There is little knowledge about exercise for patients with inclusion body myositis (IBM). Patients with IBM have limited access to rehabilitation and physiotherapy resources, despite a significant need for these services due to…
- Trial name
- NCT06644482
- Testing
- Exercise group in a hospital setting
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo University Hospital
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06371417
- Testing
- RAY121
- Where
- 77 sites in United States, Australia and 18 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
Systemic Lupus Erythematosus
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
This is a 2-part study of GSK5926371 in participants with autoimmune rheumatic diseases (ARD). In part 1, participants will receive different doses of GSK5926371 to find a suitable priming dose.
- Trial name
- ELEVATE-1 (NCT07371468)
- Testing
- GSK5926371
- Where
- 19 sites in Argentina, Brazil and 7 more
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Raynaud Phenomenon Due to Trauma, Raynaud Disease
Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud
Objective: To compare the efficacy of topical 10% nifedipine versus 5% sildenafil in patients with secondary Raynaud's phenomenon (RP).
- Conditions
- Raynaud Phenomenon Due to Trauma, Raynaud Disease, System; Sclerosis, Lupus Erythematosus, Systemic
- Trial name
- NCT03027674
- Testing
- 10% nifedipine cream, 5% sildenafil cream
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-108 in relapsed/refractory autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV)
- Trial name
- NCT06980597
- Testing
- OL-108
- Where
- 2 sites in China
- Volunteers
- 44 people
- Sponsor
- Beijing GoBroad Hospital
Rheumatoid Arthritis, Myositis
Comparison of Training Load With/Out Blood Flow Restriction Training in Rheumatoid Populations
The study will investigate the effects of a traditional, high-intensity strengthening program compared to an investigational low-intensity strengthening program that also uses blood flow restriction as part of the training…
- Conditions
- Rheumatoid Arthritis, Myositis, Osteoarthritis, Weakness, Muscle
- Trial name
- NCT04309227
- Testing
- Strength Training
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Inclusion Body Myositis (IBM)
Natalizumab in Inclusion Body Myositis (IBM)
Muscle biopsies of patients with Inclusion Body Myositis (IBM) have demonstrated a T-cell predominant inflammatory infiltrate, therefore, new agents targeting T -cell mediated cell death may be a novel treatment for IBM.
- Trial name
- IBM-NAT (NCT02483845)
- Testing
- Natalizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Phoenix Neurological Associates, LTD
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study.
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Dry Syndrome, Idiopathic Inflammatory Myopathies
- Trial name
- NCT06970951
- Testing
- UTAA91 injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Dermatomyositis, Polymyositis
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis [DM] or polymyositis [PM]).
- Trial name
- NCT06698796
- Testing
- Dazukibart
- Where
- 26 sites in United States, Argentina and 10 more
- Volunteers
- 211 people
- Sponsor
- Pfizer
SARS-CoV Infection, Systemic Disease
Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
An observational study aiming to assess the serological profile of SARS-Cov2 patients with systemic diseases such as systemic lupus erythematosus, Sjogren syndrome, sarcoidosis, inflammatory myopathies, Behçet's disease…
- Conditions
- SARS-CoV Infection, Systemic Disease, Systemic Lupus Erythematosus, Sjogren's Syndrome
- Trial name
- NCT04530461
- Testing
- Serological test
- Where
- Tunisia
- Volunteers
- 200 people
- Sponsor
- faida agili
Myositis, Idiopathic Inflammatory Myopathy
MYOPROSP - a Prospective Cohort Study in Myositis
Adult patients with suspected or confirmed idiopathic inflammatory myopathy (IIM) will be recruited. Patients will be approached, consented, have baseline demographics, diagnostics and disease activity measures recorded, and…
- Trial name
- MYOPROSP (NCT02468895)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- University of Manchester
Osteomyelitis, Septic Arthritis
Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections
The goal of this study is to figure out the best doses for two antibiotics (called cefadroxil and cephalexin) when they are used to treat bone, joint, or muscle infections in children.
- Conditions
- Osteomyelitis, Septic Arthritis, Pyomyositis
- Trial name
- NCT03802552
- Testing
- Cefadroxil, Cephalexin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Colorado, Denver
Fibrodysplasia Ossificans Progressiva (FOP)
IL1 Inhibition in FOP
This is an observational pre-post study to observe if the off label use of anti-IL1 therapies, such as anakinra or canakinumab, can block ACVR1-induced flare activity and heterotopic ossification in FOP.
- Trial name
- NCT06724562
- Testing
- Anti-IL1 Therapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, San Francisco